| 前收市價 | 8.59 |
| 開市 | 8.36 |
| 買盤 | 8.30 |
| 賣出價 | 9.80 |
| 拍板 | 35.00 |
| 到期日 | 2024-07-19 |
| 今日波幅 | 8.59 - 8.90 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 26 |
BenzingaFDA Rejects Rocket Pharmaceuticals' Gene Therapy For Rare Immune Disorder, Asks For More Data, Stock Slides
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) stock is trading down after the company announced a regulatory update for Kresladi (marnetegragene autotemcel; marne-cel), a lentiviral (LV) vector-based gene therapy to treat severe leukocyte adhesion deficiency-I (LAD-I). The FDA has issued a Complete Response Letter (CRL) to Rocket’s Biologics License Application for Kresladi, in which the FDA requested limited additional Chemistry Manufacturing and Controls (CMC) information to complete its review. Ro
ZacksWhy Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report?
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZacksRocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil
Rocket Pharmaceuticals' (RCKT) first-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.
